After years of effort, Actinium meets primary endpoint in pivotal AML trial
Actinium has made headway on a pivotal readout, and the next step is getting all the data into regulators’ hands.
The NY-based radiotherapies biotech revealed top line data Halloween morning that lead candidate Iomab-B met the primary endpoint in the pivotal Phase III SIERRA trial, testing the candidate in relapsed or refractory acute myeloid leukemia. The endpoint of the study was durable, complete remission of at least six months after initial remission, determined after a bone marrow transplant. Compared to placebo, the result was statistically significant, with a p-value of p<0.0001.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.